Wells Fargo analyst David Maris highlights Amphastar Pharmaceuticals as one of his top small-cap picks for 2017. The analyst sees three near-term catalysts for the shares, namely the FDA's action date of December 28 for Primatene Mist, the February 19, 2017 action date for the company's nasal-administered naloxone product, and the likely approval of one of the four abbreviated new drug applications for generic products Amphastar currently has filed with the agency. Maris raised his price target range for Amphastar shares to $28-$30 from $21-$23. The stock closed Thursday up 74c to $20.62.